daclizumab
Sign in to saveAlso known as Anti-IL-2, Humanized antiCD25, Ig gamma-1 chain C region, Ro-24-7375, Zinbryta
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.
Research
1,221 papers- Daclizumab Therapy for Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2019
- Daclizumab in multiple sclerosis.Revista de neurologia · 2018
- Daclizumab.Expert opinion on biological therapy · 2007
- Daclizumab for the treatment of multiple sclerosis.Neurodegenerative disease management · 2017
- Daclizumab: A Review in Relapsing Multiple Sclerosis.Drugs · 2017
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- carbon
- Has use
- medication
Show 5 more facts
- subject has role
- monoclonal antibody
- World Health Organisation international non-proprietary name
- daclizumab
- medical condition treated
- multiple sclerosis
- defined daily dose
- 0.35
- has characteristic
- biopharmaceutical
via Wikidata · CC0
~7 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Discontinued use
- Contraindications
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Research
- References
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.
In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.
Excerpted from Wikipedia’s “daclizumab” article, available under the CC BY-SA 4.0 licence.